Drug Profile
AZD 6423
Alternative Names: AZD-6423Latest Information Update: 14 Oct 2015
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class
- Mechanism of Action NMDA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Suicidal ideation
Most Recent Events
- 24 Sep 2013 Phase-I clinical trials in Suicidal ideation (in volunteers) in USA (IV)
- 19 Aug 2013 Preclinical trials in Suicidal ideation in United Kingdom (IV)
- 19 Aug 2013 AstraZeneca plans a phase I trial in Healthy volunteers in USA (NCT01926366)